You are here:

carfilzomib (Kyprolis)

Advice

following a full submission assessed under the orphan process:

carfilzomib (Kyprolis®) is accepted for use within NHS Scotland.

Indication under review: In combination with dexamethasone alone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.

Carfilzomib in combination with dexamethasone, compared with another proteasome inhibitor in combination with dexamethasone, increased progression free survival in adults with relapsed or refractory multiple myeloma who had received between one and three previous lines of treatment.

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost effectiveness of carfilzomib and is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.

This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.

Drug Details

Drug Name: carfilzomib (Kyprolis)
SMC Drug ID: 1242/17
Manufacturer: Amgen Ltd
Indication: in combination with dexamethasone alone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
BNF Category:
Submission Type: Full submission
Status: Accepted
Date Advice Published: 7 August 2017

Back